[Benefit assessment of biotechnologically produced drugs for the treatment of rheumatoid arthritis]
Institut fuer Qualitaet und Wirtschaftlichkeit im Gesundheitswesen
Record ID 32018004499
German
Original Title:
Biotechnologisch hergestellte Wirkstoffe bei rheumatoider Arthritis
Details
Project Status:
Completed
URL for project:
https://www.iqwig.de/projekte/a16-70.html
Year Published:
2019
URL for published report:
https://www.iqwig.de/download/A16-70_Biotechnologisch-hergestellte-Wirkstoffe-bei-rheumatoider-Arthritis_Abschlussbericht_V1-0.pdf
English language abstract:
There is no English language summary available
Publication Type:
Full HTA
Country:
Germany
MeSH Terms
- Arthritis, Rheumatoid
- Biological Products
- Abatacept
- Adalimumab
- Certolizumab Pegol
- Etanercept
- Infliximab
- Rituximab
- Antirheumatic Agents
- Interleukin 1 Receptor Antagonist Protein
Keywords
- Abatacept
- Adalimumab
- Anakinra
- Certolizumab Pegol
- Etanercept
- Golimumab
- Infliximab
- Rituximab
- Tocilizumab
- Arthritis - Rheumatoid
- Benefit Assessment
- Systematic Review
Contact
Organisation Name:
Institute for Quality and Efficiency in Health Care (IQWiG)
Contact Address:
IQWiG, Im Mediapark, 8, DE-50670 Cologne, GERMANY, Tel: +49(0)221-35685, Fax: +49(0)221-356851
Contact Email:
berichte@iqwig.de
Copyright:
Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.